Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
- 15 June 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 48 (4) , 377-385
Abstract
Background and Objective Underdosing of adalimumab can result in non-response and poor disease control in patients with rheumatic disease or inflammatory bowel disease. In this pilot study we aimed to predict adalimumab concentrations with population pharmacokinetic model-based Bayesian forecasting early in therapy. Methods Adalimumab pharmacokinetic models were identified with a literature search. A fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease (IBD) patients with adalimumab peak (first dose) and trough samples (first and seventh dose) obtained by a volumetric absorptive microsampling technique. Steady state adalimumab concentrations were predicted after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalised root mean square error (RMSE). Results Thirty-six patients (22 rheumatologic and 14 IBD) were analysed in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was −2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum concentrations falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable concentrations of anti-adalimumab antibodies. Conclusion This prospective study demonstrates that adalimumab concentrations at steady state can be predicted from early samples during the induction phase. Clinical Trial Registration The trial was registered in the Netherlands Trial Register with trial registry number NTR 7692 (www.trialregister.nl).Keywords
This publication has 31 references indexed in Scilit:
- Key findings towards optimising adalimumab treatment: the concentration–effect curveAnnals of the Rheumatic Diseases, 2015
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2014
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2014
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeCPT: Pharmacometrics & Systems Pharmacology, 2013
- Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s diseaseJournal of Gastroenterology, 2013
- Number and phenotype of rheumatoid arthritis patients’ CD4+CD25hi regulatory T cells are not affected by adalimumab or etanerceptRheumatology, 2011
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upJAMA, 2011
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004
- Estimating the uncertainty in estimates of root mean square error of prediction: application to determining the size of an adequate test set in multivariate calibrationChemometrics and Intelligent Laboratory Systems, 1999
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981